Goldman Sachs analyst Chris Shibutani maintained a Buy rating on BioNTech SE (BNTX – Research Report) today and set a price target of $137.00. The company’s shares closed last Friday at $99.72. Don't ...
This is a news collection page for Canberra. Check this page for latest news headlines covering major stories, events from Canberra and surrounding ACT. Get breaking news faster than any other ...
Investor's Business Daily on MSN2d
Pfizer, Moderna, BioNTech Take A Beating After Trump Taps Kennedy To Head Up HHSModerna stock and other vaccine shares tumbled Friday morning after Trump picked Kennedy to lead the Department of Health and ...
The stocks for three pharmaceutical companies heavily involved in the production of vaccines fell drastically by market close ...
With the help of TBWA\Chiat\Day New York, pharma giant Moderna is demystifying mRNA science for the average consumer. This ...
The immediate aftermath of the nomination saw vaccine stock prices drop on account of Kennedy’s well-publicized views on ...
VEGF bispecifics. | Merck and BioNTech are buying Chinese biotechs to gain PD-(L)1/VEGF bispecifics. AstraZeneca's CEO argued ...
RESEARCHERS from SINTEF have developed a “simpler” low-cost carbon capture and storage (CCS) system for sequestering ...
BioNTech to acquire clinical-stage biotech company, Biotheus to boost oncology strategy: Mainz, Germany Friday, November 15, 2024, 14:00 Hrs [IST] BioNTech SE and Biotheus (Biothe ...
The selection of vaccine sceptic Robert F Kennedy Jr by US President-elect Donald Trump to head the Department of Health and ...
Shares of vaccine makers fell as President-elect Donald Trump nominated Robert F. Kennedy Jr., a prominent vaccine skeptic, ...
Shares of prominent vaccine makers plunged Thursday after President-elect Donald Trump announced his pick of Robert F.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback